Melatonin and derivatives as promising tools for glaucoma treatment

Table 1 Hypotensive effects of melatonin analogues: animal models, conditions and receptors involved

Compound species	IOP reduction	Receptor involved	Ref.
Melatonin
Human	32.0%± 3.2%	Unknown	[7]
Rabbit	22.0% ± 1.6%	MT2, MT3	[10,11]
Mouse (glaucomatous)	33.4% ± 2.5%	MT2	UD
5-MCA-NAT
Monkey (hypertensive)	19.2% ± 2.1%	MT3	[6]
Rabbit	42.5% ± 1.6%	MT3	[10,11]
IIK7
Rabbit	38.5% ± 3.2%	MT2	[12]
INS48848
Rabbit	36.0% ± 2.0%	MT3	[22]
INS48852
Rabbit	33.1% ± 1.4%	MT2	[22]
INS48862
Rabbit	26.0 V ± 1.3 V	MT2	[22]
Agomelatine
Rabbit
Normotensive	20.8% ± 1.4%	MT2	[25]
Hypertensive	68.8% ± 5.7%	MT2	[25]

The values represent the mean ± SEM for the indicated compounds in the respective animal model. IOP: Intraocular pressure; UD: Unpublished data.